Axon Upgrade Validates Momentum but Margin Risks Keep Thesis on Hold

What happened

Axon's Q1 2026 results delivered 34% revenue growth, 44% bookings growth, and 125% NRR, prompting a Seeking Alpha upgrade to Buy based on AI-driven platform strength and 100%+ international revenue growth. However, the DeepValue master report maintains a WAIT rating, pointing to persistent tariff-driven gross margin pressure (FY2025 adjusted gross margin fell to 62.6%), a GAAP operating loss of $62.1 million, and SBC guidance of $590–$620 million for FY2026. While $14.4B in contracted bookings and 125% NRR provide strong demand visibility, valuation remains stretched at 207x EV/EBITDA with no margin of safety. The upgrade underscores near-term optimism, but the fundamental thesis hinges on proof of margin stabilization and sustained NRR above 115%—neither of which have been confirmed. Therefore, the upgrade does not change the existing wait approach; investors should await lower entry points or clear evidence of operating leverage.

Implication

Monitor Q2 2026 results for NRR trending above 115% and adjusted gross margin holding above 62%—if both hold, the bull case for re-rating gains credibility. However, failure on either metric would validate the deep-seated concerns and invite multiple compression. Position sizing should reflect asymmetric downside until the margin narrative visibly improves.

Thesis delta

The upgrade provides a positive near-term catalyst but does not alter the core thesis: AXON remains a high-quality growth compounder requiring lower entry prices or concrete proof of margin expansion. The DeepValue WAIT rating stays unchanged, as tariffs, SBC dilution, and lack of operating leverage still cloud the risk/reward.